The federal committee that monitors DNA experiments on humans will make its first judgment on a CRISPR case next week. The Recombinant DNA Advisory Committee is looking at a proposal from the University of Pennsylvania, which wants to use the gene editing technique. The plan is to harvest T-cells from cancer patients and re-program them to better fend-off cancer cells. Rather than pumping people full of debilitating drugs and hope that cancers die off, the idea is that our own immune systems can do a better job. But in order to make it work, the cells need to have certain built-in safety features shut off, hence the need for oversight.